SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001123292-23-000096
Filing Date
2023-08-14
Accepted
2023-08-14 16:41:15
Documents
3
Group Members
ASTELLAS PHARMA INC.ASTELLAS US HOLDING, INC.

Document Format Files

Seq Description Document Type Size
1 astellas13d.htm SC 13D 371013
2 EXHIBIT 2 exhibit2.htm EX-99.2 17878
3 EXHIBIT 6 exhibit6.htm EX-99.6 44403
  Complete submission text file 0001123292-23-000096.txt   434870
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Subject) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91606 | Film No.: 231171332
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 2375 WATERVIEW DRIVE NORTHBROOK IL 60062
Business Address 2375 WATERVIEW DRIVE NORTHBROOK IL 60062 800-888-7704
Astellas US LLC (Filed by) CIK: 0001989820 (see all company filings)

IRS No.: 731726638 | State of Incorp.: DE | Fiscal Year End: 0331
Type: SC 13D